- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01404416
Effect of Antenatal Iron-contained Multiple Micronutrient Supplementation, Cesarean Delivery, and CDMR on Child Health
June 4, 2015 updated by: Liu Jianmeng, Peking University
Effect of Antenatal Iron-contained Multiple Micronutrient Supplementation, Cesarean Delivery, and CDMR on Child Health- A Post-trial Follow-up Chinese Study
The follow-up study was based on our previous nutritional intervention trial entitled "Impact of Prenatal Vitamin/Mineral Supplements on Perinatal Mortality (NCT00133744)".
We followed up all livebirths born to women of the trial to measure their height, weight, and hemoglobin and to implement a questionaire survey (including developmental milestones, disease history, breast feeding, passive smoking, et al).
We selected a sub-sample of infants to assess their IQ, emotional and behavioral problem, and language development status.
The outcomes of interest include death, body mass index, overweight/ obesity, stunting/ wasting/ thinness, anemia, developmental milestones, IQ, emotional and behavioral disorder, language developmental status, and disease history.
Other interesting exposure includes breast feeding, passive smoking, et al.
We hypothesize that intrauterine nutritional exposure has an impact on offspring's physical, mental, and language development.
We also hypothesize that cesarean delivery including CDMR has an impact on offspring's these outcomes.
Study Overview
Status
Completed
Conditions
Detailed Description
The follow-up study was based on our previous nutritional intervention trial entitled "Impact of Prenatal Vitamin/Mineral Supplements on Perinatal Mortality (NCT00133744)".
We followed up all livebirths born to women of the trial to measure their height, weight, and hemoglobin and to implement a questionaire survey (including developmental milestones, disease history, breast feeding, passive smoking, et al).
We selected 1200 <30 months infants to assess their IQ with Bayley scale, emotional and behavioral problem with CBCL scale, and language development status with LDS scale.
We also selected 1500 >30 months children to measure their emotional and behavioral problem with CBCL scale.
The exposure groups include intrauterine nutritional exposure and cesarean delivery exposure as well as CDMR.
The outcomes of interest include death, body mass index, overweight/ obesity, stunting/ wasting/ thinness, anemia, developmental milestones, IQ, emotional and behavioral disorder, language developmental status, and disease history.
Other interesting exposure includes breast feeding, passive smoking, et al.
We hypothesize that intrauterine nutritional exposure has an impact on offspring's physical, mental, and language development.
We also hypothesize that cesarean delivery including CDMR has an impact on offspring's these outcomes.
Study Type
Observational
Enrollment (Actual)
17000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hebei
-
Baoding, Hebei, China
- Mancheng Maternal and Child Health Hospital
-
Langfang, Hebei, China
- Xianghe Maternal and Child Health Hospital
-
Shijiazhuang, Hebei, China
- Yuanshi Maternal and Child Health Hospital
-
Tangshan, Hebei, China
- Fengrun Maternal and Child Health Hospital
-
Tangshan, Hebei, China
- Laoting Maternal and Child Health Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 5 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
all livebirths born to women of our previous trial (NCT00133744) who were from Laoting, Fengrun, Xianghe, Mancheng, and Yuanshi counties of China.
Description
Inclusion Criteria:
- all livebirths
Exclusion Criteria:
- died
- moved out
- refused to participate
- being incapable of participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2011
Primary Completion (Actual)
September 1, 2011
Study Completion (Actual)
September 1, 2011
Study Registration Dates
First Submitted
July 27, 2011
First Submitted That Met QC Criteria
July 27, 2011
First Posted (Estimate)
July 28, 2011
Study Record Updates
Last Update Posted (Estimate)
June 8, 2015
Last Update Submitted That Met QC Criteria
June 4, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5119001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Italy, Spain, United Kingdom, Hungary
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)Netherlands, Germany, Italy, United Kingdom, United States, France
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
China Immunotech (Beijing) Biotechnology Co., Ltd.Not yet recruitingAutoimmune Hemolytic AnemiaChina
-
Peking Union Medical College HospitalNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Institute of Hematology & Blood Diseases Hospital...Not yet recruitingSevere Aplastic Anemia | Refractory Aplastic Anemia | Newly Diagnosed Aplastic Anemia
-
Chinese PLA General HospitalBeijing Friendship Hospital; Beijing 302 Hospital; The University of Hong Kong-Shenzhen... and other collaboratorsEnrolling by invitationSevere Aplastic Anemia | Severe Aplastic Anemia (SAA) | Severe Aplastic Anemia, RefractoryChina
-
Chen MiaoNot yet recruiting
-
Incyte CorporationTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom, Belgium